Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 6, Issue 4, 2014, Pages 349-368

  Roy, Aniruddha ^a   Bhattacharyya, Mousumi ^a   Ernsting, Mark J ^a,b   May, Jonathan P ^a   Li, Shyh Dar ^a,c,d  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b RYERSON UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; BIODEGRADATION; BIOPOLYMERS;

DOCETAXEL; DRUG-CONJUGATES; LOW COSTS; PACLITAXEL; RECENT PROGRESS; SIDE EFFECT; TAXANES;

DRUG PRODUCTS;

CARBOXYMETHYLCELLULOSE; CHITOSAN; DEXTRAN; DOCETAXEL; HEPARIN; HYALURONIC ACID; PACLITAXEL; POLYSACCHARIDE; ANTINEOPLASTIC AGENT; TAXOID;

ARTICLE; CANCER THERAPY; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DESIGN; DRUG RELEASE; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; TRENDS;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; HYALURONIC ACID; PACLITAXEL; POLYSACCHARIDES; TAXOIDS;

EID: 84902376377     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1264     Document Type: Article

References (77)

1. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991, 51:4845-4852.
2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265.
4. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 88:2619-2628.
5. Hsiao JR, Leu SF, Huang BM. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. J Oral Pathol Med 2009, 38:188-197.
6. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997, 48:353-374.
7. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001, 37:1590-1598.
8. Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet 1995, 345:1312-1313.
9. Baker J, Ajani J, Scotte F, Winther D, Martin M, Aapro MS, von Minckwitz G. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009, 13:49-59.
10. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
11. Drexler E, Peterson C, Pergamit G. Unbounding the Future: The Nanotechnology Revolution. New York: William Morrow and Company, Inc.; 1991.
12. Maeda H, Ueda M, Morinaga T, Matsumoto T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties. J Med Chem 1985, 28:455-461.
13. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
14. Dhal PK, Polomoscanik SC, Avila LZ, Holmes-Farley SR, Miller RJ. Functional polymers as therapeutic agents: concept to market place. Adv Drug Deliv Rev 2009, 61:1121-1130.
15. Duncan R, Vicent MJ. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 2013, 65:60-70.
16. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
17. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 2008, 16:163-169.
18. Li SD, Huang L. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 2008, 9:1317-1323.
19. Maeda H, Seymour LW, Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3:351-362.
20. Letchford K, Liggins R, Wasan KM, Burt H. In vitro human plasma distribution of nanoparticulate paclitaxel is dependent on the physicochemical properties of poly(ethylene glycol)-block-poly(caprolactone) nanoparticles. Eur J Pharm Biopharm 2009, 71:196-206.
21. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
22. Liu Z, Jiao Y, Wang Y, Zhou C, Zhang Z. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev 2008, 60:1650-1662.
23. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999, 10:755-763.
24. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000, 1:208-218.
25. Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
26. Galer CE, Sano D, Ghosh SC, Hah JH, Auzenne E, Hamir AN, Myers JN, Klostergaard J. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol 2011, 47:1039-1047.
27. Leonelli F, LaBella A, Francescangeli A, Joudioux R, Capodilupo A-L, Quagliariello M, Migneco LM, Bettolo RM, Crescenzi V, DeLuca G, et al. A new and simply available class of hydrosoluble bioconjugates by coupling paclitaxel to hyaluronic acid through a 4-hydroxybutanoic acid derived linker. Helv Chim Acta 2005, 88:154-159.
28. Rosato A, Banzato A, De Luca G, Renier D, Bettella F, Pagano C, Esposito G, Zanovello P, Bassi P. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol 2006, 24:207-215.
29. De Stefano I, Battaglia A, Zannoni GF, Prisco MG, Fattorossi A, Travaglia D, Baroni S, Renier D, Scambia G, Ferlini C, et al. Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol 2011, 68:107-116.
30. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Melendez-Alafort L, Mazzi U, Zanovello P, et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 2008, 14:3598-3606.
31. Bassi PF, Volpe A, D'Agostino D, Palermo G, Renier D, Franchini S, Rosato A, Racioppi M. Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder: results of a phase I study. J Urol 2011, 185:445-449.
32. Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 2008, 19:1319-1325.
33. Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol Cancer Ther 2013, 12:2389-2399.
34. Xin D, Wang Y, Xiang J. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res 2010, 27:380-389.
35. Thierry B, Kujawa P, Tkaczyk C, Winnik FM, Bilodeau L, Tabrizian M. Delivery platform for hydrophobic drugs: prodrug approach combined with self-assembled multilayers. J Am Chem Soc 2005, 127:1626-1627.
36. Ernsting MJ, Tang WL, MacCallum N, Li SD. Synthetic modification of carboxymethylcellulose and use thereof to prepare a nanoparticle forming conjugate of docetaxel for enhanced cytotoxicity against cancer cells. Bioconjug Chem 2011, 22:2474-2486.
37. Ernsting MJ, Tang WL, Maccallum NW, Li SD. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials 2012, 33:1445-1454.
38. Ernsting MJ, Murakami M, Undzys E, Aman A, Press B, Li SD. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. J Control Release 2012, 162:575-581.
39. Murakami M, Ernsting MJ, Undzys E, Holwell N, Foltz WD, Li SD. Docetaxel conjugate nanoparticles that target α-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Res 2013, 73:4862-4871.
40. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxel-carboxymethyl dextran conjugate, in a mouse model. Biol Pharm Bull 2008, 31:223-230.
41. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release 2007, 117:40-50.
42. Sugahara S, Kajiki M, Kuriyama H, Kobayashi TR. Paclitaxel delivery systems: the use of amino acid linkers in the conjugation of paclitaxel with carboxymethyldextran to create prodrugs. Biol Pharm Bull 2002, 25:632-641.
43. Nakamura J, Nakajima N, Matsumura K, Hyon SH. Water-soluble taxol conjugates with dextran and targets tumor cells by folic acid immobilization. Anticancer Res 2010, 30:903-909.
44. Lee E, Kim H, Lee IH, Jon S. In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration. J Control Release 2009, 140:79-85.
45. Lee E, Lee J, Lee IH, Yu M, Kim H, Chae SY, Jon S. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008, 51:6442-6449.
46. Wang Y, Xin D, Liu K, Zhu M, Xiang J. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009, 20:2214-2221.
47. Wang Y, Xin D, Liu K, Xiang J. Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm Res 2009, 26:785-793.
48. Park I-K, Kim YJ, Tran TH, Huh KM, Y-k L. Water-soluble heparin-PTX conjugates for cancer targeting. Polymer 2010, 51:3387-3393.
49. Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A, Koenig L, Giannakakou P, Shin HJ, Tighiouart M, et al. HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano 2009, 3:3165-3174.
50. Wang X, Li J, Wang Y, Koenig L, Gjyrezi A, Giannakakou P, Shin EH, Tighiouart M, Chen ZG, Nie S, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5:6184-6194.
51. Khatun Z, Nurunnabi M, Reeck GR, Cho KJ, Lee YK. Oral delivery of taurocholic acid linked heparin-docetaxel conjugates for cancer therapy. J Control Release 2013, 170:74-82.
52. Jackson DG. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol Rev 2009, 230:216-231.
53. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol Suppl 1993, 39:3-9.
54. Takeuchi K, Nakazawa M, Yamazaki H, Miyagawa Y, Ito T, Ishikawa F, Metoki T. Solid hyaluronic acid film and the prevention of postoperative fibrous scar formation in experimental animal eyes. Arch Ophthalmol 2009, 127:460-464.
55. Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010, 141:2-12.
56. Lataillade JJ, Albanese P, Uzan G. Implication of hyaluronic acid in normal and pathological angiogenesis. Application for cellular engineering. Ann Dermatol Venereol 2010, 137:S15-S22.
57. Kim IL, Mauck RL, Burdick JA. Hydrogel design for cartilage tissue engineering: a case study with hyaluronic acid. Biomaterials 2011, 32:8771-8782.
58. Wang C, Thor AD, Moore DH 2nd, Zhao Y, Kerschmann R, Stern R, Watson PH, Turley EA. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 1998, 4:567-576.
59. Kokko LL, Hurme S, Maula SM, Alanen K, Grenman R, Kinnunen I, Ventela S. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 2011, 47:510-516.
60. Qhattal HS, Liu X. Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm 2011, 8:1233-1246.
61. Zhou B, Weigel JA, Fauss L, Weigel PH. Identification of the hyaluronan receptor for endocytosis (HARE). J Biol Chem 2000, 275:37733-37741.
62. Li SD, Howell SB. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm 2010, 7:280-290.
63. Turaev AS. Dependence of the biodegradability of carboxymethylcellulose on its supermolecular structure and molecular parameters. Chem Nat Comp 1995, 31:254-259.
64. Purama RK, Goswami P, Khan AT, Goyal A. Structural analysis and properties of dextran produced by Leuconostoc mesenteroides NRRL B-640. Carbohydr Polym 2009, 76:30-35.
65. Zamani A, Edebo L, Sjostrom B, Taherzadeh MJ. Extraction and precipitation of chitosan from cell wall of zygomycetes fungi by dilute sulfuric acid. Biomacromolecules 2007, 8:3786-3790.
66. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol®) and docetaxel (Taxotere®). Cancer Treat Rev 1993, 19:351-386.
67. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost 2009, 102:258-267.
68. Niers TM, Klerk CP, DiNisio M, Van Noorden CJ, Buller HR, Reitsma PH, Richel DJ. Mechanisms of heparin induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol 2007, 61:195-207.
69. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, Kim SY, Byun Y. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006, 114:300-306.
70. Park JW, Jeon OC, Kim SK, Al-Hilal TA, Jin SJ, Moon HT, Yang VC, Kim SY, Byun Y. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. J Control Release 2010, 148:317-326.
71. Sugahara S, Okuno S, Yano T, Hamana H, Inoue K. Characteristics of tissue distribution of various polysaccharides as drug carriers: influences of molecular weight and anionic charge on tumor targeting. Biol Pharm Bull 2001, 24:535-543.
72. Duncan R, Hume IC, Kopečková P, Ulbrich K, Strohalm J, Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J Control Release 1989, 10:51-63.
73. Gander B, Gurny R, Doelker E, Peppas NA. Effect of polymeric network structure on drug release from cross-linked poly(vinyl alcohol) micromatrices. Pharm Res 1989, 6:578-584.
74. Li SD, Huang L. Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta 2009, 1788:2259-2266.
75. Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 2007, 7:216-223.
76. Pavillard V, Kherfellah D, Richard S, Robert J, Montaudon D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer 2001, 85:1077-1083.
77. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 1854-1863, 2006:5.